09 Mar Erythropoiesis Stimulating Agents: Aranesp , Epogen, and Procrit Linked to Increased Tumor Growth
The FDA informed healthcare professionals of findings from two additional clinical studies, Preoperative Epirubicin Paclitaxel Aranesp Study, and the National Cancer Institute Gynecologic Oncology Group, showing an increase in mortality and shorter time to tumor progression in patients with cancer receiving an Erythropoiesis-Stimulating Agent...